Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on April 27, 2021. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The report primarily serves as a Regulation FD disclosure regarding a new clinical adoption of the Company's technology.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused on a specific corporate event rather than a periodic financial statement (e.g., 10-K or 10-Q).
Material Changes and Events
- Clinical Adoption: Physicians at the Mayo Clinic campus in Phoenix, Arizona, have commenced using the Company's PURE EPTM System in patient cases treating cardiac arrhythmias.
- Regulatory Disclosure: The announcement was made via a press release attached as Exhibit 99.1 to ensure compliance with Regulation FD.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the strategic milestone of adoption by a major medical institution (Mayo Clinic) but does not include forward-looking financial guidance or specific sales projections.
Legal Disclaimers: The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached. The information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the commercial terms and volume of the PURE EPTM System usage at Mayo Clinic Phoenix.
- Review the attached Exhibit 99.1 (Press Release) for additional details on the scope of the deployment.
- Check subsequent periodic reports (10-Q/10-K) for any financial impact resulting from this adoption.
- Confirm the Company's current cash position and runway, as this filing does not disclose liquidity status.